Prophylactic Versus Preemptive Donor Lymphocyte Infusion in Refractory/Relapsed AML Post-Allogeneic Transplant: A Retrospective Comparative Study
Authors:
- 30 October 2025
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (3) , 302.e1-302.e10
Abstract
No abstract availableKeywords
Funding Information
- Peking University (71003Y3035)
- National Natural Science Foundation of China (82270227)
- National Natural Science Foundation of China (82470214)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z211100002921071)
- National Key Research and Development Program of China (2022YFA1103300)
- National Key Research and Development Program of China (2023YFC2508905)
This publication has 19 references indexed in Scilit:
- Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationCancer Letters, 2025
- Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patientsCancer Letters, 2024
- Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 updateCancer Letters, 2024
- Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective studyBone Marrow Transplantation, 2023
- Double-stranded RNA induction asa potential dynamic biomarkerfor DNA-demethylating agentsMolecular Therapy Nucleic Acids, 2022
- Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)Bone Marrow Transplantation, 2021
- Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experienceBone Marrow Transplantation, 2021
- The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)American Journal of Hematology, 2020
- Analysis of the Global Burden of Disease study highlights the trends in death and disability‐adjusted life years of leukemia from 1990 to 2017Cancer Communications, 2020
- Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effectBone Marrow Transplantation, 2009